# GCC Metabolomics Services Market > GCC Metabolomics Services Market Research Report By Product Type (Chromatography, Metabolomics Bioinformatics Services, Mass Spectrometry) and By Application (Biomedical and Pharmaceutical, Agriculture, Food) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 7.73% - **2024:** $ 6.43 Million - **2025:** $ 6.93 Million - **2035:** $ 14.58 Million - **Key Players:** Metabolon Inc (US), Biocrates Life Sciences AG (AT), Agilent Technologies Inc (US), Thermo Fisher Scientific Inc (US), Waters Corporation (US), PerkinElmer Inc (US), Sierra Analytics Inc (US), Creative Proteomics (US) **Report ID:** MRFR/HC/47906-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/gcc-metabolomics-services-market-49660 --- ## Market Summary ## **GCC Metabolomics Services Market Overview** As per MRFR analysis, the GCC Metabolomics Services Market Size was estimated at 104.8 (USD Million) in 2023. The GCC Metabolomics Services Market Industry is expected to grow from 117.6(USD Million) in 2024 to 472 (USD Million) by 2035. The GCC Metabolomics Services Market CAGR (growth rate) is expected to be around 13.466% during the forecast period (2025 - 2035) **Key GCC Metabolomics Services Market Trends Highlighted** In the GCC Metabolomics Services Market, there is a growing emphasis on precision medicine and personalized healthcare solutions. Governments in the region are investing in biotechnology and health research, as highlighted by initiatives aimed at advancing health technologies across member states such as the UAE and Saudi Arabia. These efforts are coupled with a rising awareness of the importance of metabolomics in understanding diseases and enhancing treatment modalities.  Additionally, collaborations between research institutions and private entities are gaining traction as stakeholders seek to leverage advanced analytical techniques and technologies.This trend fosters innovation in metabolomics services, including the development of tailored diagnostic tools and therapies. The increasing prevalence of chronic diseases in the GCC, such as obesity and diabetes, creates a strong demand for metabolomics services, further driving market growth.  There are significant opportunities to be explored in fields like agriculture and nutrition, as metabolomics can enhance crop yield and food quality, aligning with the GCC's focus on food security and sustainability. With the rise of government-backed health initiatives, the adoption of integrated healthcare solutions is also becoming prominent, presenting further openings in the market. The focus on improving healthcare outcomes through data-driven insights in metabolomics is likely to expand, leading to more innovative solutions in addressing regional health issues. Moreover, with the convergence of technology and healthcare, a shift towards digital health solutions in metabolomics can also be anticipated, adding another layer to the evolving market landscape. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **GCC Metabolomics Services Market Drivers** **Increasing Healthcare Expenditure in GCC Countries** One of the main factors propelling the GCC Metabolomics Services Market Industry is the rising healthcare spending in the GCC nations. The World Bank reports that investments in health services have increased to around 8.3% of GDP in the GCC, reflecting a notable increase in health spending in these nations. The government's efforts to address health issues and enhance the country's healthcare systems are primarily responsible for this rise.  Furthermore, according to the United Arab Emirates' Ministry of Health and Prevention, healthcare expenditures are expected to exceed USD 20 billion by 2025, which increases demand for sophisticated diagnostic services like metabolomics. As governments seek to improve health outcomes through precision medicine and customized treatment choices, these growing investments are anticipated to encourage the usage of metabolomics services, propelling market expansion in the GCC area. **Rising Prevalence of Chronic Diseases** The GCC region has registered a significant rise in the prevalence of chronic diseases such as diabetes, cardiovascular diseases, and cancer. Data from the Organization for Economic Cooperation and Development (OECD) reported that the region is experiencing a 20% increase in diabetes rates, projecting about 2.7 million adults with diabetes in the GCC countries by 2030.  This alarming trend prompts faster health interventions and the adoption of metabolomics services, as these services can provide insights into disease progression and help in developing effective treatment plans tailored for individuals.The increased focus on managing chronic diseases through novel approaches like metabolomics will strengthen the demand for related services in the GCC Metabolomics Services Market Industry. **Government Initiatives and Support for Biotechnology Research** Governments in the GCC region are taking proactive measures to support biotechnology research, which significantly aids the GCC Metabolomics Services Market. For instance, the Saudi Arabian government has earmarked USD 1.4 billion for healthcare innovation and biotechnology research initiatives as part of its Vision 2030 strategy. This strategic focus on fostering research capabilities and creating knowledge-based economies lays the groundwork for enhanced metabolomics studies and service offerings in the region.As a result, increased governmental funding and support are leading to advancements in metabolomic technologies and applications, boosting growth in the market as researchers and healthcare providers leverage these advancements to improve patient outcomes. **GCC Metabolomics Services Market Segment Insights** **Metabolomics Services Market Product Type Insights** The GCC Metabolomics Services Market is experiencing notable advancements, particularly within the Product Type segment, comprising Chromatography, Metabolomics Bioinformatics Services, and Mass Spectrometry. This segment plays a crucial role in understanding metabolic profiles and provides the necessary tools for drug development, diagnostics, and personalized medicine. The rising incidences of chronic diseases in the GCC region, along with increasing investments in Research and Development, are propelling the demand for sophisticated metabolomics services. Chromatography dominates this segment due to its efficiency in separating complex mixtures, enabling the precise analysis of various biomolecules.  Its utility in pharmaceutical applications, particularly for quality control and assurance, makes it indispensable for the region's growing pharmaceutical industry. On the other hand, Metabolomics Bioinformatics Services is becoming increasingly important as it provides essential analytical capabilities needed for interpreting large datasets generated from high-throughput technologies. The capacity to integrate biological data with computational algorithms aids researchers and healthcare professionals in predictive modeling, further enhancing the understanding of metabolic functions and biomarker discovery.  Mass Spectrometry stands out for its accuracy in quantifying metabolites, thus facilitating both clinical and preclinical research. Its significance in the GCC Metabolomics Services Market industry cannot be understated, as it supports critical applications like toxicology and environmental assessments. Additionally, governmental initiatives aimed at funding health research and the establishment of specialized healthcare facilities in the GCC are set to stimulate further growth in this segment.  The interplay of these various components within the Product Type segment highlights the intricate dynamics at work in the GCC Metabolomics Services Market, emphasizing its role in advancing health sciences and personalized therapies in the region. As the demand for innovative healthcare solutions continues to grow, the relevance of these metabolomics services remains pivotal, suggesting a future trajectory of sustained market progress and potential expansion. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Metabolomics Services Market Application Insights** The Application segment of the GCC Metabolomics Services Market plays a crucial role in the market's growth, driven by advancements in technology and an increasing focus on precision medicine and agriculture. The Biomedical and Pharmaceutical sector is particularly significant as it leverages metabolomics to enhance drug development, disease diagnosis, and personalized therapies, aligning with the GCC region's commitment to advancing healthcare systems.  Meanwhile, the Agriculture segment benefits from metabolomics by improving crop yield, pest resistance, and understanding plant metabolic pathways, which is aligned with GCC countries' initiatives to enhance food security.Additionally, the Food industry utilizes metabolomics for quality control, safety assessments, and nutritional profiling, responding to the rising demand for transparency in food supply chains.  The GCC Metabolomics Services Market segmentation highlights the diversity and depth of applications, showcasing a comprehensive approach to health, agriculture, and food safety, which are pivotal in the region's economic diversification efforts and sustainable development strategies. Enhanced technological integration and growing awareness about the benefits of metabolomics are key factors propelling growth within these applications, further establishing their importance and relevance in the GCC landscape. **GCC Metabolomics Services Market Key Players and Competitive Insights** The GCC Metabolomics Services Market has gained considerable attention in recent years due to its crucial role in advancing healthcare and pharmaceutical research. This market involves the analysis of metabolites within biological samples, providing insights into metabolic processes and potential biomarkers for disease diagnosis and treatment. Competitive dynamics in the GCC region are shaped by various factors, including technological advancements, research collaborations, and the increasing demand for personalized medicine. Companies operating in this space are focused on building robust service portfolios that leverage innovative technologies to cater to the unique needs of regional customers while also addressing the regulatory considerations and market access challenges prevalent in the GCC countries. AB Sciex is recognized as a prominent player within the GCC Metabolomics Services Market, leveraging its extensive experience and advanced technologies in mass spectrometry. The company has established a strong presence in the region, supported by a comprehensive suite of analytical solutions that facilitate metabolomics research and diagnostics. One of the key strengths of AB Sciex lies in its commitment to innovation, regularly updating its product offerings to meet the evolving needs of researchers and clinicians.  Their state-of-the-art instruments are widely used in both academic research institutions and pharmaceutical companies across the GCC, enabling high-throughput analysis and ensuring data accuracy and reliability. Additionally, AB Sciex actively engages in partnerships and collaborations that enhance its service capabilities, allowing the company to maintain a competitive edge in the market and cater effectively to the specific requirements of the GCC healthcare landscape.Fluxion Biosciences has established itself as an influential entity in the GCC Metabolomics Services Market, offering cutting-edge solutions tailored to the region’s scientific community.  The company specializes in integrated technologies that enable high-resolution analysis of cellular metabolism, thereby playing a pivotal role in supporting research and development efforts in drug discovery and personalized medicine. Fluxion's key products include advanced microfluidic platforms and instrumentation that facilitate rapid and precise metabolic profiling. Their market presence in the GCC is bolstered by strategic collaborations and partnerships aimed at expanding their reach and enhancing service delivery.  Furthermore, Fluxion has been involved in several mergers and acquisitions that have strengthened its technological capabilities and expanded its product portfolio, allowing it to address diverse research needs effectively within the region. With a focus on innovation and technological advancement, Fluxion Biosciences continues to solidify its position as a key contributor in the GCC metabolomics landscape. **Key Companies in the GCC Metabolomics Services Market Include** **GCC Metabolomics Services Market Industry Developments** In recent months, the GCC Metabolomics Services Market has witnessed significant developments, driven by advancements in technologies and increasing demand for personalized medicine. Companies like AB Sciex, Thermo Fisher Scientific, and Agilent Technologies have been at the forefront, enhancing their service offerings and expanding capabilities in biosample analysis. In September 2023, Metabolon announced an expansion of its services in the UAE, focusing on disease-specific metabolomics, which reflects the region's growing emphasis on healthcare innovations.  In the past two years, the region has experienced a notable market valuation increase attributed to partnerships among firms such as Celerion and Charles River Laboratories for optimizing drug development processes. In addition, recent mergers and acquisitions have included a strategic partnership between Fluxion Biosciences and local firms to better cater to the burgeoning biotechnology sector, enhancing their market presence. The rising investing environment in GCC countries, such as Saudi Arabia's Vision 2030 initiative, has further spurred investments in metabolomics research and innovation, establishing a robust foundation for future growth in this sector. **GCC Metabolomics Services Market Segmentation Insights** ## Market Drivers ### Rising Healthcare Expenditure The increasing healthcare expenditure in the GCC region is a pivotal driver for the metabolomics services market. As governments and private sectors allocate more funds towards healthcare, there is a growing emphasis on advanced diagnostic tools and personalized treatment options. In 2025, healthcare spending in the GCC is projected to reach approximately $100 billion, reflecting a compound annual growth rate (CAGR) of around 7%. This financial commitment facilitates the adoption of metabolomics services, which are essential for understanding complex biological processes and developing targeted therapies. Consequently, the metabolomics services market is likely to experience substantial growth as healthcare providers seek innovative solutions to enhance patient outcomes and streamline treatment protocols. ### Emergence of Biopharmaceuticals The biopharmaceutical sector is experiencing rapid growth in the GCC, which is significantly impacting the metabolomics services market. As biopharmaceutical companies seek to develop novel therapies, they require comprehensive metabolic profiling to understand drug interactions and patient responses. The GCC biopharmaceutical market is expected to reach $20 billion by 2026, indicating a robust demand for metabolomics services that can support drug development processes. This growth is likely to foster collaborations between biopharmaceutical firms and metabolomics service providers, enhancing the overall market landscape. The integration of metabolomics into biopharmaceutical research may lead to more effective treatments and improved patient outcomes. ### Advancements in Research Infrastructure The GCC region is witnessing substantial investments in research infrastructure, which is a key driver for the metabolomics services market. Enhanced laboratory facilities and technological advancements are enabling researchers to conduct more sophisticated metabolic analyses. Governments are increasingly funding research initiatives, with an estimated $5 billion allocated to scientific research in 2025. This investment is likely to bolster the capabilities of metabolomics service providers, allowing them to offer more accurate and comprehensive analyses. As research institutions collaborate with healthcare providers, the demand for metabolomics services is expected to rise, facilitating breakthroughs in various fields, including drug discovery and disease prevention. ### Growing Awareness of Preventive Healthcare There is a notable shift towards preventive healthcare in the GCC, which is influencing the metabolomics services market. As populations become more health-conscious, there is an increasing demand for services that can provide insights into metabolic health and disease risk. The emphasis on preventive measures is prompting healthcare providers to incorporate metabolomics into routine health assessments. This trend is expected to drive market growth, as individuals seek personalized health solutions based on metabolic profiles. With an anticipated increase in preventive healthcare initiatives, the metabolomics services market is likely to expand, offering innovative tools for early detection and lifestyle management. ### Increased Focus on Chronic Disease Management The rising prevalence of chronic diseases in the GCC region is driving demand for metabolomics services. Chronic conditions such as diabetes, cardiovascular diseases, and cancer are becoming more common, necessitating advanced diagnostic and therapeutic approaches. The metabolomics services market plays a crucial role in identifying biomarkers that can aid in early detection and personalized treatment strategies. With an estimated 30% of the population in the GCC affected by chronic diseases, healthcare systems are increasingly investing in metabolomics to improve patient management and outcomes. This trend suggests that the metabolomics services market will continue to expand as healthcare providers prioritize innovative solutions for chronic disease management. ## Future Outlook The [Metabolomics Services Market](https://www.marketresearchfuture.com/reports/metabolomics-services-market-8435) is projected to grow at a 7.73% CAGR from 2025 to 2035, driven by advancements in technology, increasing research funding, and rising demand for personalized medicine. **New opportunities:** - Development of integrated metabolomics platforms for clinical diagnostics. - Expansion of metabolomics services into agricultural biotechnology applications. - Partnerships with pharmaceutical companies for drug discovery and development. By 2035, the metabolomics services market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Product and Service: Chromatography (Largest) vs. Mass Spectrometry (Fastest-Growing) In the GCC metabolomics services market, Chromatography holds the largest market share among the product and service segment values, reflecting its critical role in biochemical analysis and compound separation. Following closely, Mass Spectrometry is gaining traction, noted for its advanced capabilities and precision in identifying and quantifying metabolites, presenting a robust distribution in the current scientific landscape. The growth trends in the product and service segment are being propelled by advancements in technology and the increasing demand for personalized medicine. Bioinformatics services are also emerging as valuable tools, integrating vast metabolic data with analytical techniques to derive meaningful insights. The heightened focus on research and development in various domains such as pharmaceuticals and agriculture further enhances the growth potential, making this segment a focal point for investment and innovation. Chromatography (Dominant) vs. Bioinformatics Services (Emerging) Chromatography stands out as the dominant force in the GCC metabolomics services market, known for its effectiveness in separating complex mixtures into individual components. Its utility spans various applications including pharmaceuticals, environmental testing, and food safety, driven by extensive research demands. On the other hand, Bioinformatics Services are positioned as an emerging player, harnessing computational tools to analyze metabolomic data, enabling researchers to extract meaningful biological insights. This segment is rapidly gaining importance due to the increasing volumes of data generated from metabolomics studies, necessitating sophisticated analytical approaches. As the market evolves, both segments are expected to play pivotal roles in shaping the future landscape of metabolomics. ### By Application: Biomedical and Pharmaceutical (Largest) vs. Agriculture (Fastest-Growing) The GCC metabolomics services market displays a diverse distribution among its key application segments. The Biomedical and Pharmaceutical segments hold a significant share, largely driven by advancements in drug development and personalized medicine. In contrast, Agriculture has been gaining traction as it integrates metabolomics for crop improvement and disease management, carving out its niche in the market. Growth trends in the GCC metabolomics services market are influenced by several factors. The rising demand for precision medicine and agricultural solutions underlines the importance of metabolomics in both the health and agricultural sectors. Furthermore, increased R&D expenditure and collaborations between academic and private sectors are fostering innovation in metabolomics applications, driving the overall growth of the market. Biomedical and Pharmaceutical (Dominant) vs. Agriculture (Emerging) The Biomedical and Pharmaceutical application segment stands out as the dominant force in the GCC metabolomics services market, benefiting from robust investment and a focus on biopharmaceutical innovation. This segment leverages metabolomics for drug discovery, biomarker identification, and the development of personalized medicine approaches, enhancing patient outcomes. On the other hand, the Agriculture segment is emerging rapidly as a critical player, utilizing metabolomics techniques for crop enhancement, pest resistance, and sustainable agricultural practices. This growth is particularly driven by the increasing need for food security and sustainable farming methods in the GCC region, positioning Agriculture as a vital area for future developments, particularly in precision agriculture. ### Metabolomics Services Market Application Insights Metabolomics Services Market Application Insights The Application segment of the GCC Metabolomics Services Market plays a crucial role in the market's growth, driven by advancements in technology and an increasing focus on precision medicine and agriculture. The Biomedical and Pharmaceutical sector is particularly significant as it leverages metabolomics to enhance drug development, disease diagnosis, and personalized therapies, aligning with the GCC region's commitment to advancing healthcare systems.  Meanwhile, the Agriculture segment benefits from metabolomics by improving crop yield, pest resistance, and understanding plant metabolic pathways, which is aligned with GCC countries' initiatives to enhance food security.Additionally, the Food industry utilizes metabolomics for quality control, safety assessments, and nutritional profiling, responding to the rising demand for transparency in food supply chains.  The GCC Metabolomics Services Market segmentation highlights the diversity and depth of applications, showcasing a comprehensive approach to health, agriculture, and food safety, which are pivotal in the region's economic diversification efforts and sustainable development strategies. Enhanced technological integration and growing awareness about the benefits of metabolomics are key factors propelling growth within these applications, further establishing their importance and relevance in the GCC landscape. ## Competitive Benchmarking The metabolomics services market is currently characterized by a dynamic competitive landscape, driven by advancements in analytical technologies and an increasing focus on personalized medicine. Key players such as Metabolon Inc (US), Biocrates Life Sciences AG (AT), and Agilent Technologies Inc (US) are strategically positioned to leverage these trends. Metabolon Inc (US) emphasizes innovation in metabolomic profiling, while Biocrates Life Sciences AG (AT) focuses on expanding its product offerings in targeted metabolomics. Agilent Technologies Inc (US) is enhancing its capabilities through strategic partnerships, thereby shaping a competitive environment that is increasingly collaborative and innovation-driven.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market appears moderately fragmented, with several players vying for market share. However, the collective influence of major companies is significant, as they drive technological advancements and set industry standards, thereby influencing smaller players and new entrants. In October In October 2025, Metabolon Inc (US) announced a partnership with a leading pharmaceutical company. This partnership aims to develop a novel metabolomic platform that accelerates drug discovery. This strategic move is likely to enhance Metabolon’s market position by integrating its advanced metabolomic technologies with the pharmaceutical partner's extensive research capabilities, potentially leading to faster and more efficient drug development processes. In September Biocrates Life Sciences AG (AT) launched a new suite of targeted metabolomics kits designed for clinical research applications. This introduction not only expands their product portfolio but also positions them to capture a larger share of the clinical research market, which is increasingly recognizing the value of metabolomics in understanding disease mechanisms and treatment responses. In August Agilent Technologies Inc (US) unveiled a new software platform that integrates AI-driven analytics with its metabolomics instrumentation. This development is indicative of a broader trend towards digitalization in the metabolomics services market, as companies seek to enhance data analysis capabilities and improve the accuracy of metabolomic profiling. As of November current competitive trends are heavily influenced by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are becoming increasingly important, as companies recognize the need for collaboration to drive innovation and enhance service offerings. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological innovation, reliability in supply chains, and the ability to deliver personalized solutions. This shift underscores the importance of adaptability and forward-thinking strategies in maintaining a competitive edge in the metabolomics services market. ## Recent News & Developments In recent months, the GCC Metabolomics Services Market has witnessed significant developments, driven by advancements in technologies and increasing demand for personalized medicine. Companies like AB Sciex, Thermo Fisher Scientific, and Agilent Technologies have been at the forefront, enhancing their service offerings and expanding capabilities in biosample analysis. In September 2023, Metabolon announced an expansion of its services in the UAE, focusing on disease-specific metabolomics, which reflects the region's growing emphasis on healthcare innovations.  In the past two years, the region has experienced a notable market valuation increase attributed to partnerships among firms such as Celerion and Charles River Laboratories for optimizing drug development processes. In addition, recent mergers and acquisitions have included a strategic partnership between Fluxion Biosciences and local firms to better cater to the burgeoning biotechnology sector, enhancing their market presence. The rising investing environment in GCC countries, such as Saudi Arabia's Vision 2030 initiative, has further spurred investments in metabolomics research and innovation, establishing a robust foundation for future growth in this sector. ## Report Scope | MARKET SIZE 2024 | 6.43(USD Million) | | --- | --- | | MARKET SIZE 2025 | 6.93(USD Million) | | MARKET SIZE 2035 | 14.58(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.73% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Metabolon Inc (US), Biocrates Life Sciences AG (AT), Agilent Technologies Inc (US), Thermo Fisher Scientific Inc (US), Waters Corporation (US), PerkinElmer Inc (US), Sierra Analytics Inc (US), Creative Proteomics (US) | | Segments Covered | Product and Service, Application | | Key Market Opportunities | Integration of advanced analytics in metabolomics services enhances precision medicine and personalized healthcare solutions. | | Key Market Dynamics | Rising demand for personalized medicine drives growth in metabolomics services across the GCC region. | | Countries Covered | GCC | ## Frequently Asked Questions **Q: What is the projected market valuation for the GCC metabolomics services market in 2035?** A: The projected market valuation for the GCC metabolomics services market in 2035 is expected to reach $14.58 Million. **Q: What was the market valuation for the GCC metabolomics services market in 2024?** A: The market valuation for the GCC metabolomics services market was $6.43 Million in 2024. **Q: What is the expected CAGR for the GCC metabolomics services market during the forecast period 2025 - 2035?** A: The expected CAGR for the GCC metabolomics services market during the forecast period 2025 - 2035 is 7.73%. **Q: Which companies are considered key players in the GCC metabolomics services market?** A: Key players in the GCC metabolomics services market include Metabolon Inc, Biocrates Life Sciences AG, Agilent Technologies Inc, and Thermo Fisher Scientific Inc. **Q: What are the main product and service segments in the GCC metabolomics services market?** A: The main product and service segments in the GCC metabolomics services market include Chromatography, Mass Spectrometry, and Metabolomics Bioinformatics Services. **Q: What is the valuation of the Mass Spectrometry segment in the GCC metabolomics services market?** A: The valuation of the Mass Spectrometry segment in the GCC metabolomics services market was $2.93 Million in 2024 and is projected to reach $6.58 Million by 2035. **Q: How does the Biomedical and Pharmaceutical application segment perform in the GCC metabolomics services market?** A: The Biomedical and Pharmaceutical application segment was valued at $2.58 Million in 2024 and is expected to grow to $5.85 Million by 2035. **Q: What is the growth potential of the Agriculture application segment in the GCC metabolomics services market?** A: The Agriculture application segment was valued at $1.93 Million in 2024 and is projected to increase to $4.38 Million by 2035. **Q: What is the expected growth for the Food application segment in the GCC metabolomics services market?** A: The Food application segment was valued at $2.92 Million in 2024 and is anticipated to reach $4.35 Million by 2035. **Q: How do the key players influence the GCC metabolomics services market?** A: Key players like Waters Corporation and PerkinElmer Inc likely influence the GCC metabolomics services market through innovation and competitive strategies. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/gcc-metabolomics-services-market-49660*